Biohaven price target raised to $60 from $59 at BTIG

BTIG analyst Thomas Shrader raised the firm’s price target on Biohaven (BHVN) to $60 from $59 and keeps a Buy rating on the shares. The company’s SCA saga seem near its end, and the firm sees the final Biohaven arguments as solid and likely to be reviewed by an FDA eager to do something that looks patient-friendly in an orphan disease, the analyst tells investors in a research note.